Sustained Or Differential Release Type Patents (Class 424/468)
  • Patent number: 11351213
    Abstract: The present invention relates to a composition comprising or, alternatively, consisting of an effective amount of a mixture which comprises at least, or consists of: a) an extract of Pelargonium sidoides; b) an extract of Adhatoda vasica; and c) N-acetyl cysteine for use in a method for the preventive or therapeutic treatment of at least one respiratory tract disorder in a subject, wherein said treatment method comprises the administration of said composition to the subject.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: June 7, 2022
    Assignee: NEILOS S.R.L.
    Inventor: Umberto Di Maio
  • Patent number: 11344494
    Abstract: The present invention provides an impregnated porous carrier material comprising at least one active pharmaceutical ingredient (API) impregnated throughout the internal surface of a porous carrier. The present invention further provides immediate release and sustained release pharmaceutical dosage forms comprising the impregnated porous carrier material disclosed herein such that any single active pharmaceutical ingredient (API) content variability in the finished drug product has a relative standard deviation of less than 3%.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: May 31, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Fernando J. Muzzio, Benjamin J. Glasser, Plamen I. Grigorov
  • Patent number: 11331281
    Abstract: Mixture of stabilised biologically available curcumin for orodispersible formulations, formulations of biologically available curcumin and orodispersible tablet with biologically available curcumin and its application. An orodispersible tablet with biologically available curcumin contains particles of extract of rhizome of plant Curcuma longa, which contains, at least, 95% by weight of curcumin, grounded to size 100 to 250 nm in mixture with mannitol in weight ratio 1 to 3:1 (mannitol:curcumin). Orodispersible tablet also contains an orodispersible carrier, and curcumin 100% biologically available through oral mucosa.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: May 17, 2022
    Inventors: Jan Stonis, Ivan Mikes, Andrea Dolezalova, Jarmila Kralova, Milan Jakubek, Pavel Martasek, Vladimir Kral
  • Patent number: 11311488
    Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: April 26, 2022
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
  • Patent number: 11304906
    Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: April 19, 2022
    Assignee: XWPHARMA LTD.
    Inventors: Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Nicolas D. Kirkland
  • Patent number: 11241377
    Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: February 8, 2022
    Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.
    Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
  • Patent number: 11229619
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: January 25, 2022
    Assignee: Biogen Swiss Manufacturing GmbH
    Inventors: Henrik Nilsson, Bernd W. Mueller
  • Patent number: 11224615
    Abstract: Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe2+ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: January 18, 2022
    Assignee: SOLVOTRIN THERAPEUTICS LTD
    Inventors: John Gilmer, Radics Gabor, Michael Whelehan, Jun Wang, Pat O'Flynn, Mark Ledwidge
  • Patent number: 11207271
    Abstract: The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: December 28, 2021
    Assignee: NLS Pharmaceutics AG
    Inventors: Alexander C. Zwyer, Lewis P. Amsel, Virginia Schmith, Scott Brantley
  • Patent number: 11173148
    Abstract: The present invention relates to a sustained-release pharmaceutical composition intended for animal use, which comprises a drug, a sugar, a wax, and a water-soluble polymer.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 16, 2021
    Assignee: DS PHARMA ANIMAL HEALTH CO., LTD.
    Inventor: Teruaki Kuriyama
  • Patent number: 11147273
    Abstract: The present invention encompasses a stabilized parasiticidal granule composition comprising a macrocyclic lactone compound and an insect growth regulator. The invention also encompasses methods of making and methods of using the granule for treating, controlling or preventing parasitic infestation or parasitic infection in an animal.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 19, 2021
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Kour Chand Jindal, Jian Han, Kim Agnew
  • Patent number: 11135175
    Abstract: A microcapsule includes an active component encapsulated within a polymerized hydrolyzed protein shell. The microcapsule has an average diameter that is less than one hundred micrometers as determined by a laser diffractometer.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: October 5, 2021
    Assignee: Anabio Technologies Limited
    Inventor: Sinead Doherty
  • Patent number: 11129837
    Abstract: A liquid composition contains a salicylate compound (e.g. aspirin), glycerin triacetate, saccharin. The salicylate compound is soluble in the composition, which is particularly suitable for oral, parenteral or pulmonary administration.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 28, 2021
    Assignee: INNOVATE PHARMACEUTICALS LIMITED
    Inventors: Simon Jason Cohen, Craig Hurst
  • Patent number: 11123331
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 21, 2021
    Assignee: VELOXIS PHARMACEUTICALS, INC.
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11110081
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 7, 2021
    Assignee: VELOXIS PHARMACEUTICALS, INC.
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11111400
    Abstract: Some embodiments are directed to a multimaterial powder used in the field of metallurgy and plasturgy. The multimaterial powder includes support particles having a median particle size distribution between 1 ?m and 100 ?m and functionalising particles having a median particle size distribution that is a factor of 10 to 1000 lower relative to the support particles. The powder is characterised in that the support particles and the functionalising particles form composite grains having a core-shell structure that each have a core formed by a support particle, and a shell, that covers between 10 and 100% of the surface of the support particle and which is formed by at least one surface layer of the functionalising particles.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 7, 2021
    Assignee: H.E.F.
    Inventors: Constantin Iacob, Sébastien Bucher, Fabrice Prost, Christophe Heau
  • Patent number: 11052074
    Abstract: The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-? and anti-TGF-?1 action for the treatment of hepatic fibrosis.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: July 6, 2021
    Assignee: Excalibur Pharmaceuticals, Inc.
    Inventors: Juan Socorro Armendáriz Borunda, José Agustín Rogelio Magaña Castro, Jorge Cervantes Guadarrama
  • Patent number: 11040030
    Abstract: The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-? and anti-TGF-?1 action for the treatment of hepatic fibrosis.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 22, 2021
    Assignee: Excalibur Pharmaceuticals, Inc.
    Inventors: Juan Socorro Armendáriz Borunda, José Agustín Rogelio Magaña Castro, Jorge Cervantes Guadarrama
  • Patent number: 11013751
    Abstract: Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: May 25, 2021
    Assignee: Vitalis LLC
    Inventor: Joseph Habboushe
  • Patent number: 11000481
    Abstract: The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole. The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: May 11, 2021
    Assignee: KOREA UNITED PHARM. INC.
    Inventors: Youn Woong Choi, Hee Yong Song, Dae-Chul Ha, Byung Jin Kim
  • Patent number: 10987309
    Abstract: The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: April 27, 2021
    Assignee: ETHYPHARM
    Inventors: Catherine Herry, Pauline Contamin
  • Patent number: 10980747
    Abstract: A composition which is used for the production of a solid preparation exhibiting a small variation of dissolution even at a low content of hydroxypropyl methyl cellulose (HPMC), and others. More specifically, provided are a composition for a solid preparation, the composition including HPMC having a polydispersity of 4.0 or more, as determined by absolute molecular weight measurement, and having a viscosity at 20° C. of 1,500 to 15,0000 mPa·s, as determined in a 2% by mass aqueous solution thereof, and an active ingredient; the solid preparation including the composition; and a method for producing a tablet including a step of dry-mixing said HPMC with an active ingredient to obtain a mixture, or granulating a mixture including said HPMC and an active ingredient to obtain a granulated product, and a step of tableting the mixture or the granulated product to obtain a tablet.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: April 20, 2021
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventor: Takuya Yokosawa
  • Patent number: 10966989
    Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 6, 2021
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10946002
    Abstract: The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 16, 2021
    Inventors: Kamal Surendrakumar Mehta, Dinesh Kumar, Saurabh Srivastava, Basudev Paul
  • Patent number: 10946026
    Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 16, 2021
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10940113
    Abstract: A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: March 9, 2021
    Assignee: MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER
    Inventors: Chih-Chiang Yang, Wen-Che Wang, Chiao-Ling Hsu
  • Patent number: 10940115
    Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: March 9, 2021
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Bernard Charles Sherman, Michael Spino
  • Patent number: 10912762
    Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: February 9, 2021
    Assignee: LABORATOIRES MAJOR
    Inventors: Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
  • Patent number: 10888522
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Patent number: 10888528
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: January 12, 2021
    Assignee: Clexio Biosciences Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
  • Patent number: 10869860
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: December 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
  • Patent number: 10864199
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 15, 2020
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 10739319
    Abstract: A method for analyzing related substances in a pharmaceutical composition containing an amphiphilic block copolymer comprising a hydrophilic block and a hydrophobic block as a polymeric drug carrier, related substances identified thereby, and a method for evaluating a pharmaceutical composition by using the same are provided. Preferably, the method comprises evaluating a polymeric micelle pharmaceutical composition, which comprises an amphiphilic block copolymer comprising a hydrophilic block (A) and a hydrophobic block (B), and paclitaxel or docetaxel as a poorly water-soluble drug, by using a compound represented by Chemical Formula 1, wherein the hydrophilic block (A) comprises one or more selected from the group consisting of polyethylene glycol or derivatives thereof, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide and combinations thereof; and the hydrophobic block (B) is polylactide.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: August 11, 2020
    Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Hye Rim Kim, Ji Yeong Kim, Bum Chan Min, Min Hyo Seo, Ho Joon Choi
  • Patent number: 10729657
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: August 4, 2020
    Assignee: OHEMO Life Sciences Inc.
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 10722473
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 28, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Graeme Donnelly, Sailaja Bhaskar
  • Patent number: 10695294
    Abstract: A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: June 30, 2020
    Assignee: Sigrid Therapeutics AB
    Inventors: Robert Csikasz, Tore Bengtsson, Natalia Kupferschmidt, Alfonso E. Garcia-Bennett
  • Patent number: 10696751
    Abstract: Provided are a solid preparation comprising an alkyl cellulose which provides excellent moldability and disintegrability even in a small amount of the alkyl cellulose, and a production method therefor. Specifically, provided are a solid preparation having an alkyl cellulose having a specific surface area by BET method of 0.5 to 10.0 m2/g and a dissolution start temperature of 5 to 27° C.; and a method for producing a solid preparation having the steps of: mixing a cellulose pulp and a first alkali metal hydroxide solution with stirring to obtain alkali cellulose, reacting the alkali cellulose with an alkylating agent to obtain a first reaction mixture, mixing the first reaction mixture and a second alkali metal hydroxide solution with stirring and without further addition of any alkylating agent to obtain a second reaction mixture, and pulverizing an alkyl cellulose isolated from the second reaction mixture to obtain an alkyl cellulose.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: June 30, 2020
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Takuya Yokosawa, Naosuke Maruyama, Akira Kitamura
  • Patent number: 10688179
    Abstract: Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: June 23, 2020
    Inventor: Richard Louis Price
  • Patent number: 10675247
    Abstract: A press coated tablet for delayed release of an active ingredient comprising: (a) a core comprising one or more active ingredients, and; (b) an erodible delayed release barrier surrounding the core and comprising a wax and two or more grades of L-HPC, wherein the wax and L-HPC are provided in a weight ratio of wax to L-HPC of from 30%:70% to 70%:30%. The invention also relates to a method of making the press coated tablet.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 9, 2020
    Assignee: Drug Delivery International Ltd.
    Inventors: Howard Norman Ernest Stevens, Alexander Balfour Mullen, David Smith, Fiona Jane Macdougall, Vivekanand Bhardwaj
  • Patent number: 10668050
    Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: June 2, 2020
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg
  • Patent number: 10645923
    Abstract: An insect bait that can be carried by the insect, that includes a toxicant capable of killing insects in a nest, and that includes attractants, having at least one non-toxic layer that delays contact with the toxicant, wherein the size, shape and attractants attract the insect to take the whole of the bait to a nest situation where further manipulation of the bait by the insect will release the toxicant.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: May 12, 2020
    Inventor: Carina Hiley
  • Patent number: 10583146
    Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: March 10, 2020
    Assignee: SHIRE VIROPHARMA INCORPORATED
    Inventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
  • Patent number: 10561602
    Abstract: A controlled extended release composition comprising at least one unit dosage form having at least one active pharmaceutical ingredient (API), wherein said at least one API comprises at least one of pregabalin, a base thereof, a pharmaceutically acceptable prodrug thereof, a pharmaceutically acceptable derivative thereof, a pharmaceutically acceptable complex thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymorph thereof, a pharmaceutically acceptable hydrate thereof, a pharmaceutically acceptable solvate thereof, an enantiomer thereof and a racemate thereof. Methods and uses of the composition are provided.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: February 18, 2020
    Inventor: Isa Odidi
  • Patent number: 10537530
    Abstract: The invention provides a gastric resistant, enteric-coated solid dosage form including a core containing a pharmaceutically active ingredient, an inner coating for the core, and an outer enteric coating. The inner coating comprises an anionic polymeric material or a water-soluble neutral polymeric material, and further comprises a water soluble inorganic salt which is not a carbonate or bicarbonates. The outer enteric coating comprises an anionic polymeric material which is less neutralized than the polymeric material comprising the inner coating and disintegrates rapidly at a pH of 5.5 to 7.0 upon entering the small intestine.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 21, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Fang Liu, Abdul W. Basit, Rosario Lizio, Hans-Ulrich Petereit, Christian Meier, Michael Damm
  • Patent number: 10537526
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 21, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10534895
    Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: January 14, 2020
    Assignee: ICPD Technologies, LLC
    Inventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
  • Patent number: 10517840
    Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 31, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Richard John Dansereau, Daren Anness, Guhan Balan, David Ramsey
  • Patent number: 10507205
    Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Lars Hermann
  • Patent number: 10471025
    Abstract: The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: November 12, 2019
    Inventors: Nuno Afonso, Sara Sousa, Rita Vaz, Diana Chapela, Sofia Côrte-Real
  • Patent number: 10463622
    Abstract: Disclosed herein are treatments for diseases such as hypertension, diabetes, and congestive heart failure using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 5, 2019
    Inventor: Salim Shah